

Additional file 1. Patients with prescriptions for ARBs or ACE inhibitors***

	Study population	ARB* or ACEi** Number of patients with at least 1 such prescription
Number (percentage) of patients with CKD and:	556 (100%)	261 (47%)
<i>Diabetes: n (%)</i>	<i>215 (38%)</i>	<i>115 (53%)</i>
Diabetes and heart failure stage I-II: n (%)	53 (9.5%)	29 (55%)
Diabetes and heart failure stage III-IV	28 (5.0%)	13 (46%)
Diabetes and no heart failure	134 (24.1%)	73 (54%)
<i>Chronic Heart Failure: n (%)</i>	<i>104 (19%)</i>	<i>42 (40%)</i>
Heart failure stage I-II and no diabetes;	65 (11.7%)	26 (40%)
Heart failure stage III-IV and no diabetes	39 (7.0%)	16 (41%)
<i>CKD without heart failure or diabetes: n (%)</i>	<i>225 (40.5%)</i>	<i>104 (40%)</i>
<i>According to nephropathy</i>		
Vascular	103 (45.2%)	56 (54%)
Cystic	43 (18.9%)	14 (32%)
Chronic glomerulonephritis	30 (13.2%)	11 (37%)
Unknown	49 (21.5%)	23 (47%)

* ARB: Angiotensin receptor blocker

* ACEi: Angiotensin-converting enzyme inhibitor